UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2012

Lifevantage Corporation

(Exact name of registrant as specified in its charter)

Colorado (State or other Jurisdiction of Incorporation) 001-35647 (Commission File Number) 90-0224471 (IRS Employer Identification No.)

9815 S. Monroe Street, Suite 100, Sandy, UT (Address of Principal Executive Offices) 84070 (Zip Code)

Registrant's telephone number, including area code: (801) 432-9000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

D Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On November 14, 2012, Lifevantage Corporation issued a press release. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished in this Item 8.01 and the exhibit hereto shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit Number Description

99.1 Press release issued on November 14, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 14, 2012

Lifevantage Corporation

By: /s/ Rob Cutler

Rob Cutler General Counsel & Secretary



LifeVantage Announces Dismissal of Lawsuit

SALT LAKE CITY, November 14, 2012 (GLOBE NEWSWIRE) — LifeVantage Corporation (NASDAQ:LFVN), announced today that on November 13, 2012, the Plaintiff in the lawsuit entitled *Bramwell* v. *LifeVantage Corporation, et al* (No. 12 Civ. 1006 (DB)), unilaterally dismissed the action by filing a Notice of Voluntary Dismissal in the United States District Court for the District of Utah under Rule 41(a)(1)(A) of the Federal Rules of Civil Procedure. The dismissal resulted from no settlement or consideration provided by or on behalf of LifeVantage or any of the other defendants.

About LifeVantage Corporation

LifeVantage Corporation, a leader in Nrf2 science and the maker of Protandim[®], the Nrf2 Synergizer[®] patented dietary supplement, is a science based nutraceutical company. LifeVantage is dedicated to visionary science that looks to transform wellness and anti-aging internally and externally with products that dramatically reduce oxidative stress at the cellular level. The Company was founded in 2003 and is headquartered in Salt Lake City, UT.

Investor Relations Contact:

Cindy England 801.432.9036 Director of Investor Relations -or-John Mills 310.954.1105 Senior Managing Director, ICR, LLC